{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:26:14Z","timestamp":1791012374704,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T00:00:00Z","timestamp":1300147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T00:00:00Z","timestamp":1300147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s10637-011-9651-3","type":"journal-article","created":{"date-parts":[[2011,3,14]],"date-time":"2011-03-14T05:40:30Z","timestamp":1300081230000},"page":"1164-1174","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic\/recurrent pancreatic cancer: combined analysis with translational research"],"prefix":"10.1007","volume":"30","author":[{"given":"Do-Youn","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hak","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Young","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun-Mo","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Suk","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong-Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Jue","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,15]]},"reference":[{"key":"9651_CR1","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris III","year":"1997","unstructured":"Burris HA III, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413","journal-title":"J Clin Oncol"},{"key":"9651_CR2","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","volume":"20","author":"JD Berlin","year":"2002","unstructured":"Berlin JD, Catalano P, Thomas JP et al (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270\u20133275","journal-title":"J Clin Oncol"},{"key":"9651_CR3","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/cncr.10323","volume":"94","author":"G Colucci","year":"2002","unstructured":"Colucci G, Giuliani F, Gebbia V et al (2002) Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and\/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell\u2019Italia Meridionale. Cancer 94:902\u2013910","journal-title":"Cancer"},{"key":"9651_CR4","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1093\/annonc\/mdi309","volume":"16","author":"H Oettle","year":"2005","unstructured":"Oettle H, Richards D, Ramanathan RK et al (2005) A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16:1639\u20131645","journal-title":"Ann Oncol"},{"key":"9651_CR5","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1200\/JCO.2004.12.082","volume":"22","author":"CM Rocha Lima","year":"2004","unstructured":"Rocha Lima CM, Green MR, Rotche R et al (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776\u20133783","journal-title":"J Clin Oncol"},{"key":"9651_CR6","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","volume":"23","author":"C Louvet","year":"2005","unstructured":"Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509\u20133516","journal-title":"J Clin Oncol"},{"key":"9651_CR7","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960\u20131966","journal-title":"J Clin Oncol"},{"key":"9651_CR8","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1200\/JCO.2007.13.0401","volume":"25","author":"RA Miksad","year":"2007","unstructured":"Miksad RA, Schnipper L, Goldstein M (2007) Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 25:4506\u20134507","journal-title":"J Clin Oncol"},{"key":"9651_CR9","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","volume":"25","author":"R Herrmann","year":"2007","unstructured":"Herrmann R, Bodoky G, Ruhstaller T et al (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212\u20132217","journal-title":"J Clin Oncol"},{"key":"9651_CR10","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","volume":"27","author":"D Cunningham","year":"2009","unstructured":"Cunningham D, Chau I, Stocken DD et al (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513\u20135518","journal-title":"J Clin Oncol"},{"key":"9651_CR11","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1200\/JCO.1991.9.11.2042","volume":"9","author":"DL Longo","year":"1991","unstructured":"Longo DL, Duffey PL, DeVita VT Jr et al (1991) The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 9:2042\u20132051","journal-title":"J Clin Oncol"},{"key":"9651_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/sj.bjc.6601487","volume":"90","author":"S Marsh","year":"2004","unstructured":"Marsh S, McLeod HL (2004) Cancer pharmacogenetics. Br J Cancer 90:8\u201311","journal-title":"Br J Cancer"},{"key":"9651_CR13","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1038\/onc.2009.158","volume":"28","author":"H Akita","year":"2009","unstructured":"Akita H, Zheng Z, Takeda Y et al (2009) Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 28:2903\u20132909","journal-title":"Oncogene"},{"key":"9651_CR14","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/cncr.22559","volume":"109","author":"J Lee","year":"2007","unstructured":"Lee J, Jang KT, Ki CS et al (2007) Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 109:1561\u20131569","journal-title":"Cancer"},{"key":"9651_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/sj.clpt.6100087","volume":"81","author":"KM Giacomini","year":"2007","unstructured":"Giacomini KM, Brett CM, Altman RB et al (2007) The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 81:328\u2013345","journal-title":"Clin Pharmacol Ther"},{"key":"9651_CR16","first-page":"1009","volume":"9","author":"W Liu","year":"2003","unstructured":"Liu W, Innocenti F, Chen P et al (2003) Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 9:1009\u20131012","journal-title":"Clin Cancer Res"},{"key":"9651_CR17","doi-asserted-by":"publisher","first-page":"13176","DOI":"10.1074\/jbc.274.19.13176","volume":"274","author":"F Gebhardt","year":"1999","unstructured":"Gebhardt F, Zanker KS, Brandt B (1999) Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 274:13176\u201313180","journal-title":"J Biol Chem"},{"key":"9651_CR18","doi-asserted-by":"publisher","first-page":"9139","DOI":"10.1158\/0008-5472.CAN-04-1036","volume":"64","author":"ML Amador","year":"2004","unstructured":"Amador ML, Oppenheimer D, Perea S et al (2004) An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 64:9139\u20139143","journal-title":"Cancer Res"},{"key":"9651_CR19","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-07-0088","volume":"13","author":"J Li","year":"2007","unstructured":"Li J, Zhao M, He P et al (2007) Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13:3731\u20133737","journal-title":"Clin Cancer Res"},{"key":"9651_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/00007691-200404000-00019","volume":"26","author":"L Wojnowski","year":"2004","unstructured":"Wojnowski L (2004) Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 26:192\u2013199","journal-title":"Ther Drug Monit"},{"key":"9651_CR21","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/ijc.22390","volume":"120","author":"S Nakahira","year":"2007","unstructured":"Nakahira S, Nakamori S, Tsujie M et al (2007) Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120:1355\u20131363","journal-title":"Int J Cancer"},{"issue":"suppl 6","key":"9651_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/00001813-199512006-00002","volume":"6","author":"W Plunkett","year":"1995","unstructured":"Plunkett W, Huang P, Gandhi V (1995) Preclinical characteristics of gemcitabine. Anticancer Drugs 6(suppl 6):7\u201313","journal-title":"Anticancer Drugs"},{"key":"9651_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.2006.06.7405","volume":"25","author":"E Sugiyama","year":"2007","unstructured":"Sugiyama E, Kaniwa N, Kim S-R et al (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25:32\u201342","journal-title":"J Clin Oncol"},{"key":"9651_CR24","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1158\/0008-5472.CAN-05-4203","volume":"66","author":"E Giovannetti","year":"2006","unstructured":"Giovannetti E, Del Tacca M, Mey V et al (2006) Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66:3928\u20133935","journal-title":"Cancer Res"},{"key":"9651_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.2006.06.7405","volume":"25","author":"E Sugiyama","year":"2007","unstructured":"Sugiyama E, Kaniwa N, Kim SR et al (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25:32\u201342","journal-title":"J Clin Oncol"},{"key":"9651_CR26","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1080\/15257770802145447","volume":"27","author":"E Giovannetti","year":"2008","unstructured":"Giovannetti E, Laan AC, Vasile E et al (2008) Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 27:720\u2013725","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"9651_CR27","first-page":"4304","volume":"9","author":"Y Yen","year":"2003","unstructured":"Yen Y (2003) Ribonucleotide reductase subunit one as gene therapy target. Clin Cancer Res 9:4304\u20134308","journal-title":"Clin Cancer Res"},{"key":"9651_CR28","first-page":"4204","volume":"59","author":"YG Goan","year":"1999","unstructured":"Goan YG, Zhou B, Hu E et al (1999) Overexpression of ribonucleotide reductase as a mechanism of resistance to 2, 2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59:4204\u20134207","journal-title":"Cancer Res"},{"key":"9651_CR29","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/ijc.22390","volume":"120","author":"S Nakahira","year":"2007","unstructured":"Nakahira S, Nakamori S, Tsujie M et al (2007) Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120:1355\u20131363","journal-title":"Int J Cancer"},{"key":"9651_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00535-007-2017-0","volume":"42","author":"T Itoi","year":"2007","unstructured":"Itoi T, Sofuni A, Fukushima N et al (2007) Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinoma. J Gastroenterol 42:389\u2013394","journal-title":"J Gastroenterol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-011-9651-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9651-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9651-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:24:34Z","timestamp":1678559074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-011-9651-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,15]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["9651"],"URL":"https:\/\/doi.org\/10.1007\/s10637-011-9651-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,15]]},"assertion":[{"value":"8 February 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}